Organon team in Australia growing to support dedicated focus on women’s health
September 28, 2021 12:04 pm EDT
Growing a business with a commitment to listen to women to understand her health needs requires different thinking and approaches
Just four months since its launch as the only global company of its size focused on women’s health, Organon in Australia continues to invest in people to deliver on its focus on women’s health through its portfolios of women’s contraception and fertility, biosimilars and established brands.
One unique approach has been to attract people from outside of the traditional pharma sector for fresh eyes and fresh ideas. In just four short months, Organon has grown its employee founder base with six senior positions filled from diverse industries including the construction, FMCG, Medical Devices, automotive and political sectors.
“We have brought in external people that are non-pharma, and already we’re seeing new perspectives, new reference points and new approaches – opening our lateral and strategic thinking. We embrace the different insights and energy and we’re saying don’t wait to settle in, we want to hear your ideas now,” said Nirelle Tolstoshev, Managing Director, Organon ANZ.
Attracting the best people to support Organon’s strategy to lead and evolve as a progressive, future fit and dynamic organisation is proving to be a successful part of Organon’s success, including two additions to the Organon Leadership Team, with Sophie Althans commencing as HR Director and Mark Coleman taking the role of Strategy and Organisational Development Lead.
Sophie is a member of both the ANZ Leadership Team and the Regional HR Leadership Team. She will oversee the continuing development of Organon ANZ’s people and culture of engagement to support short term business execution and long-term transformation. Sophie has a wealth of experience in supporting organisations to achieve their business priorities through driving effective talent strategies. As well as expertise in the pharmaceutical sector, Sophie has also worked in Medical Devices, Supply Chain and FMCG.
Mark Coleman joins in a novel role specifically designed to lead Organon’s organisational development strategy. Mark has over 20 years’ experience in healthcare, and is passionate about helping teams thrive through creating environments that enable learning, reflection and growth.
In an early indication of the commitment to a culture of people first, entrepreneurship, and a mindset focused on future requirements, Mark will support the organisation to realise the company vision and values.
“With their deep expertise in people, processes to foster learning, business excellence, and continuous improvement for growth, I am confident that Sophie and Mark will make great contributions to our business,” said Nirelle Tolstoshev.
Organon in Australia is one of the few markets globally to have all three core pillars of Women’s Health, Biosimilars and Established Brands.
Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck& Co., Kenilworth, NJ, USA (NYSE: MRK) known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey, USA.
Forward-Looking Statement of Organon
Except for historical information herein, this news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future financial performance and prospects. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict its future financial results and performance; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).